Core F: Long-Term Follow-Up. This core supports Projects 1- 6 by collecting long-term follow-up data for patients who have had hematopoietic cell transplantation at the Seattle Cancer Care Alliance, University of Washington Medical Center or Children's Hospital and Regional Medical Center under protocols developed at the Fred Hutchinson Cancer Research Center as part of clinical research studies sponsored by this program. The data provided through Core F are required for a variety of critically important purposes by projects in this program: 1) capture of longer-term outcomes, including the occurrence of chronic GVHD, infections, recurrent or progressive malignancy, secondary malignancy and other anticipated late complications, as well as dates of last contact and death for patients enrolled in prospective research trials, 2) capture of similar observational data for patients not enrolled in prospective studies, to be used for retrospective studies, 3) capture of observational data to be used for planning new clinical trials, and 4) capture of survivorship information to identify previously unrecognized late effects. A variety of mechanisms will be used to support these goals. a) We will continue to collect long-term data focused on survival, therapy-related complications, health and health-related quality of life relevant to the clinical research studies sponsored by this grant. These data concern the retrospective cohort of patients currently in follow-up from previous studies and the prospective cohort of patients to be enrolled .in studies described in Projects 1 - 6 of this grant application. For this purpose, a system has been established to track and maintain contact with patients and referring physicians so that data can be collected at specified time points after treatment. b)We will continue to assist investigators in obtaining long-term data specifically needed for individual research projects. c) We will continue to evaluate the methods employed in data collection and database management, identify barriers that interfere with long-term follow-up, and explore new technology to improve the efficiency and reliability of data collection and the validity and utility of the data. Relevance to Public Health: The data generated from this core unit will assist project leaders in the identification of late complications In patients who have had blood or marrow cell transplantation for treatment of leukemia, lymphoma, myeloma and other related disorders. The data will also provide the basis for hypothesis-driven research concerning risk factors for late complications, the mechanisms leading to late complications, and the development of new approaches for preventing and managing late complications among cancer survivors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA018029-35
Application #
8073197
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2010-03-01
Budget End
2011-02-28
Support Year
35
Fiscal Year
2010
Total Cost
$394,331
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Schmitt, Michael W; Pritchard, Justin R; Leighow, Scott M et al. (2018) Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias. Clin Cancer Res 24:5321-5334
Shaw, Bronwen E; Syrjala, Karen L; Onstad, Lynn E et al. (2018) PROMIS measures can be used to assess symptoms and function in long-term hematopoietic cell transplantation survivors. Cancer 124:841-849
Jamani, Kareem; Onstad, Lynn E; Bar, Merav et al. (2018) Quality of Life of Caregivers of Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 24:2271-2276
Ogimi, Chikara; Xie, Hu; Leisenring, Wendy M et al. (2018) Initial High Viral Load Is Associated with Prolonged Shedding of Human Rhinovirus in Allogeneic Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 24:2160-2163
Salter, Alexander I; Pont, Margot J; Riddell, Stanley R (2018) Chimeric antigen receptor-modified T cells: CD19 and the road beyond. Blood 131:2621-2629
Lee, Stephanie J; Nguyen, Tam D; Onstad, Lynn et al. (2018) Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:555-562
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313
Armenian, Saro H; Yang, Dongyun; Teh, Jennifer Berano et al. (2018) Prediction of cardiovascular disease among hematopoietic cell transplantation survivors. Blood Adv 2:1756-1764
Petersdorf, Effie W; Stevenson, Philip; Malkki, Mari et al. (2018) Patient HLA Germline Variation and Transplant Survivorship. J Clin Oncol 36:2524-2531
Yeung, Cecilia C S; McElhone, Scott; Chen, Xue Yan et al. (2018) Impact of copy neutral loss of heterozygosity and total genome aberrations on survival in myelodysplastic syndrome. Mod Pathol 31:569-580

Showing the most recent 10 out of 1845 publications